SEC Form 4 · accession 0001140361-17-045941
Emergent BioSolutions Inc. · EBS
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Ronald Richard
Director
Period of report
Dec 12, 2017
Accepted (ET)
Dec 13, 2017 · 8:20 am EST
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001367644
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common StockF1 | Dec 12, 2017 | M | 23,681 | $10.64 | A | 47,091 | D | |
| Common StockF1,F2 | Dec 12, 2017 | S | 23,681 | $45.0245 | D | 23,410 | D |
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Employee Stock Option (Right to buy)F3,F4 | $10.64 | Dec 12, 2017 | M | 23,681 | D | — | May 21, 2019 | Common Stock | 23,681 | 0 | D |
Explanation of responses
- F1The transaction reported in this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by Mr. Richard.
- F2The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $45.00 to $45.17, inclusive.
- F3Consists of an option granted under the company's stock incentive plan as amended and restated.
- F4The option grant is fully vested.